

FUND AT A GLANCE

AS PROVIDED AND CONFIRMED BY FUND MANAGER

SCHEME CATEGORISATION

Alternative Investment Fund

LAUNCH DATE

01 March 2017

SCHEME STRATEGY

Private Equity

TARGET RETURN

£1.70 for every £1 invested

TARGET DIVERSIFICATION

3 - 8 investee companies

CUSTODIAN: Woodside Corporate Services Ltd

NOMINEE: WCS Nominees Ltd

INVESTMENT SECTOR



Life Sciences

CLOSING DATES:
Evergreen

DEPLOYMENT TIME FRAME:
Monthly

FUND MANAGER



AUM

£166m

DATE OF FCA AUTHORISATION

03 December 2020

INVESTMENT OBJECTIVE

The investment strategy of the Deepbridge Life Sciences EIS is to invest in a diversified portfolio of up to ten investee companies that participate in one of the following: Biopharmaceuticals; Biotechnology; or Medical Technology. The Deepbridge Life Sciences Team seeks to invest in companies that possess some or all of the following attributes:

- A focus on life sciences and medical device technology;
- Significant market potential with clear need and market growth;
- Provide a solution to a recognised clinical or healthcare need;
- Innovation-driven products that have the potential to create new market segments or displace current technologies;
- Medical technology businesses with a clear and realistic path to commercialisation;
- Robust intellectual property which may provide patented or patentable IP protection;
- Passionate, energetic, experienced and aligned founding team;
- Clear exit strategy to be implemented within 4-5 years with alignment of interests with our stakeholders.

Please note that not all attributes may be achievable in each investment.

EXIT STRATEGY

The Deepbridge Team believes that most exits in the technology sector will take place in the M&A space, and so aim to execute business models suitable for this exit route. The Deepbridge team will assess any opportunity to capitalise on exit opportunities, notwithstanding the 3 year EIS period, if an early exit is in investors' best interests.

Deepbridge believes that either a sale of the investee companies, or a sale or refinancing of the assets owned by the investee companies, will enable funds to be returned to Investors.

Fee type	Fees charged to the investor (including VAT)	Fees charged to Investee Companies (including VAT)
Initial fee	n/a	6.00%
Annual management fee	n/a	2.40%
Performance fee	20%*	n/a
Other fee information	n/a	0.50% - Custodian Fee

*Performance Incentive Fee: Once the investor has received in cash the first 120 pence per 100 pence invested (ignoring any tax relief and representing a 20% hurdle rate on funds invested).

Important Notice

The information and wording contained in this document is provided and confirmed by fund manager. This brochure is for discussion purposes only for financial advisers and other FCA regulated firms who are considering investment options for their clients. Other persons who receive this document by accident should disregard the content.

The underlying investments accessed through Kuber are often illiquid and therefore high risk and will not be suitable for all investors. Please ensure you have considered the risks set out in the documentation for an investment before making a recommendation. Tax reliefs are personal to investors' circumstances and tax regimes may change.

This financial promotion has been approved for the purposes of section 21 of the FSMA by Oxygen Ventures Ltd which is authorised and regulated by the Financial Conduct Authority (FCA) under number 208188. Kuber Ventures Limited is an Appointed Representative of Oxygen Ventures Limited under number 574987.

Need to know more?

Get in touch:

+44 (0) 20 7952 6685

info@kuberventures.com

www.kuberventures.com